Aubagne

Sartorius Stedim Biotech acquires cell culture specialist Xell AG

Retrieved on: 
Jeudi, juillet 29, 2021

AUBAGNE, France, July 29, 2021 /PRNewswire/ -- The life science company Sartorius Stedim Biotech acquired cell culture specialist XellAG headquartered in Bielefeld, Germany.

Key Points: 
  • AUBAGNE, France, July 29, 2021 /PRNewswire/ -- The life science company Sartorius Stedim Biotech acquired cell culture specialist XellAG headquartered in Bielefeld, Germany.
  • "I would like to cordially welcome the Xell team to Sartorius Stedim Biotech and am looking forward to our collaboration in this demanding time."
  • "Sartorius Stedim Biotech, with its strong sales team and complementary product portfolio, offers an excellent platform for further expansion, and we are extremely excited about our joint future development," added Stefan Northoff, CEO of Xell AG.
  • Xell AG is a globally active biotech company with a strong focus on cell culture media as well as associated analytical and process services.

Sartorius Stedim Biotech SA: Information on Document Availability

Retrieved on: 
Mercredi, juillet 21, 2021

Sartorius Stedim Biotech SA

Sartorius Stedim Biotech SA: Information on Document Availability 21-Jul-2021 / 07:05 CET/CEST

Dissemination of a French Regulatory News, transmitted by EQS Group.

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The report on the first half 2021 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:
    It contains the following information:
    Consolidated financial statements for the period ended June 30, 2021
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Sartorius Stedim Biotech strengthens product portfolio for cell and gene therapies by acquiring a majority stake in CellGenix

Retrieved on: 
Vendredi, juillet 2, 2021

AUBAGNE, France, July 2, 2021 /PRNewswire/ -- Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has acquired a majority stake in the reagent manufacturer CellGenix GmbH.

Key Points: 
  • AUBAGNE, France, July 2, 2021 /PRNewswire/ -- Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has acquired a majority stake in the reagent manufacturer CellGenix GmbH.
  • Sartorius Stedim Biotech has initially acquired 51 percent of this company, which has been privately owned until now, for around 100millioneuros in cash.
  • At the beginning of 2023 and 2026, Sartorius Stedim Biotech plans to acquire the remaining shares of CellGenix.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.

Sartorius Stedim Biotech SA: Implementation of a new contract of liquidity with Kepler Cheuvreux

Retrieved on: 
Mardi, mai 4, 2021

of the French Commercial Code, and the AMF decision no.

Key Points: 
  • of the French Commercial Code, and the AMF decision no.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.

Retrieved on: 
Mercredi, mars 24, 2021

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.

Key Points: 
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Sartorius Stedim Biotech increases its full-year 2021 guidance

Retrieved on: 
Jeudi, mars 18, 2021

AUBAGNE, France, March 18, 2021 /PRNewswire/ -- Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, Sartorius Stedim Biotech has raised its growth forecast for fiscal 2021.

Key Points: 
  • AUBAGNE, France, March 18, 2021 /PRNewswire/ -- Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, Sartorius Stedim Biotech has raised its growth forecast for fiscal 2021.
  • The major part of the expected additional business is related to the coronavirus pandemic as many products of Sartorius Stedim Biotech are used for manufacturing vaccines.
  • Sartorius Stedim Biotech will publish first quarter 2021 figures as scheduled on April 21, 2021.
  • Furthermore, Sartorius Stedim Biotech reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided.

Sartorius Stedim Biotech SA: Information on Document Availability

Retrieved on: 
Jeudi, février 18, 2021

It contains the following information:

Key Points: 
  • It contains the following information:
    - Consolidated financial statements for the year ended December 31, 2020
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.68 euros per share to Annual Shareholders' Meeting

Retrieved on: 
Vendredi, février 5, 2021

AUBAGNE, France, Feb. 5, 2021 /PRNewswire/ -- The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today's meeting to submit a proposal to the combined Annual General Shareholders' Meeting on March 24, 2021, to pay a dividend for fiscal 2020 of 0.68 euros per share.

Key Points: 
  • AUBAGNE, France, Feb. 5, 2021 /PRNewswire/ -- The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today's meeting to submit a proposal to the combined Annual General Shareholders' Meeting on March 24, 2021, to pay a dividend for fiscal 2020 of 0.68 euros per share.
  • This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.
  • Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation.

Sartorius Stedim Biotech to acquire Novasep's chromatography process equipment division

Retrieved on: 
Mercredi, janvier 6, 2021

AUBAGNE, France, Jan. 6, 2021 /PRNewswire/ -- Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, today announced it has entered into an agreement to acquire the chromatography process equipment division of Novasep.

Key Points: 
  • AUBAGNE, France, Jan. 6, 2021 /PRNewswire/ -- Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, today announced it has entered into an agreement to acquire the chromatography process equipment division of Novasep.
  • Since 2018, Novasep and Sartorius Stedim Biotech have been collaborating in the joint development of an optimized system for a membrane-based, low-pressure chromatography that processes larger molecules more productively and will be launched soon.
  • "I am pleased that we will intensify our successful collaboration with the Novasep team, soon to be under the Sartorius Stedim Biotech roof," said Dr. Ren Fber, Member of the Board of Directors of Sartorius Stedim Biotech.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.

Sartorius Stedim Biotech acquires filtration expert WaterSep BioSeparations

Retrieved on: 
Mercredi, décembre 9, 2020

AUBAGNE, France, Dec. 9, 2020 /PRNewswire/ -- Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, today acquired U.S.-based purification expert WaterSepBioSeparationsLLC.

Key Points: 
  • AUBAGNE, France, Dec. 9, 2020 /PRNewswire/ -- Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, today acquired U.S.-based purification expert WaterSepBioSeparationsLLC.
  • "I am pleased to welcome the WaterSep team to Sartorius Stedim Biotech and look forward to jointly introducing WaterSep BioSeparations innovative solutions to ourcustomers."
  • WaterSep is excited to join the Sartorius Stedim Biotech team as they continue to lead the transformation of bioprocessing to single use," said AttilaHerczeg, CEO and President of WaterSep BioSeparations.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.